8-K: Illumina Returns to Growth, Projects 4-6% Revenue Increase

Illumina reported a strong finish to fiscal year 2025 with a return to growth, driven by clinical market expansion and strategic acquisitions, and provided optimistic 2026 guidance.

Summary

• Fourth quarter 2025 revenue reached $1.16 billion, marking a 5% increase from Q4 2024 (4% on a constant currency basis).
• Ex-China revenue for Q4 2025 was $1.10 billion, up 8% from Q4 2024 (7% on a constant currency basis).
• GAAP diluted EPS for Q4 2025 was $2.16, while non-GAAP diluted EPS was $1.35.
• Fiscal year 2025 revenue was $4.34 billion, flat compared to 2024 on both a reported and constant currency basis.
• Ex-China revenue for fiscal year 2025 was $4.10 billion, up 2% from 2024.
• GAAP diluted EPS for fiscal year 2025 was $5.45, and non-GAAP diluted EPS was $4.84.
• For fiscal year 2026, total company revenue is expected to be $4.5 billion to $4.6 billion, representing 4%-6% growth, including a 1.5%-2.0% benefit from the SomaLogic acquisition.
• Ex-China Organic revenue growth for FY 2026 is projected at 2%-4%.
• Non-GAAP operating margin for FY 2026 is guided to be in the range of 23.3%-23.5%, including a negative impact of 100bps from the SomaLogic acquisition.
• Non-GAAP diluted EPS for FY 2026 is expected to be in the range of $5.05-$5.20, including $0.18 in dilution from the SomaLogic acquisition.
• Illumina completed the acquisition of SomaLogic, introduced the Billion Cell Atlas with partners like AstraZeneca, Merck, and Eli Lilly, and appointed Eric Green as Chief Medical Officer.
• The Chinese Ministry of Commerce (MOFCOM) lifted the export ban on Illumina sequencers, though the company remains on the Unreliable Entities List (UEL) in China.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting a return to growth and strategic advancements, despite some dilutive effects from acquisitions and ongoing challenges in the China market.

Positives

• Delivered a strong finish to 2025, marking a return to growth through disciplined execution.
• Q4 2025 revenue increased by 5% to $1.16 billion, with ex-China revenue up 8%.
• Q4 2025 GAAP diluted EPS of $2.16 significantly exceeded Q4 2024's $0.73.
• Q4 2025 non-GAAP diluted EPS of $1.35 improved from $0.95 in Q4 2024.
• Fiscal year 2026 guidance projects total company revenue growth of 4%-6% and an increase in non-GAAP diluted EPS to $5.05-$5.20 from $4.84 in FY 2025.
• Completed the acquisition of SomaLogic, expanding the multiomics portfolio and strengthening its position in scalable, NGS-enabled proteomics.
• Introduced the Billion Cell Atlas, the first data product of the BioInsight business, with major pharmaceutical partners (AstraZeneca, Merck, and Eli Lilly).
• Appointed veteran genomics leader Eric Green, MD, PhD, as Chief Medical Officer to advance clinical genomics.
• The Chinese Ministry of Commerce (MOFCOM) lifted the export ban on Illumina sequencers.

Negatives

• Fiscal year 2025 revenue was flat compared to 2024 at $4.34 billion.
• FY 2025 GAAP diluted EPS of $5.45 was lower than $5.61 in 2024.
• The SomaLogic acquisition is expected to have a negative impact of 100bps on non-GAAP operating margin and $0.18 dilution on non-GAAP diluted EPS in FY 2026.
• Illumina remains on the Unreliable Entities List (UEL) in China, requiring approvals for instrument purchases.
• Cash flow provided by operations decreased to $321 million in Q4 2025 from $364 million in Q4 2024.
• Free cash flow decreased to $267 million in Q4 2025 from $322 million in Q4 2024.

Risks

• Changes in the rate of growth in the markets served, including the proteomics market.
• The volume, timing, and mix of customer orders among products and services.
• Ability to adjust operating expenses to align with revenue expectations.
• Ability to successfully integrate SomaLogic, Inc. and certain other acquired assets into existing operations and technology portfolio.
• Ability to successfully manage partner and customer relationships in the proteomics market.
• Uncertainty regarding the impact of inclusion on the unreliable entities list by regulatory authorities in China.
• Uncertainty regarding tariffs imposed or threatened by the U.S. government and its trading partners.
• Ability to manufacture robust instrumentation and consumables, including SomaLogic Business products.
• Success of products and services competitive with Illumina's own.
• Challenges inherent in developing, manufacturing, and launching new products and services, including reliance on third-party suppliers.
• The impact of recently launched or pre-announced products and services on existing products and services.
• Ability to modify business strategies to accomplish desired operational goals.
• Ability to realize anticipated benefits from prior or future actions to streamline R&D processes, reduce operating expenses, and maximize revenue growth.
• Ability to further develop and commercialize instruments, consumables, and products, and to expand markets for technology platforms.
• The risk of additional litigation arising in connection with the GRAIL acquisition.
• Ability to obtain approval by third-party payors to reimburse patients for products.
• Ability to obtain regulatory clearance for products from government agencies.
• Ability to successfully partner with other companies and organizations.
• Uncertainty or adverse economic and business conditions, including slowing economic growth or armed conflict.
• The application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments.
• Legislative, regulatory, and economic developments.

Future Outlook

For fiscal year 2026, Illumina expects total company revenue of $4.5 billion to $4.6 billion, representing 4%-6% growth, including a 1.5%-2.0% benefit from the SomaLogic acquisition. Ex-China Organic revenue growth is projected at 2%-4%. Non-GAAP operating margin is anticipated to be in the range of 23.3%-23.5%, with a 100bps negative impact from SomaLogic. Non-GAAP diluted EPS is guided to be $5.05-$5.20, including $0.18 dilution from SomaLogic.

Management Comments

• "The Illumina team delivered a strong finish to 2025, marking a return to growth through disciplined execution against our strategy."
• "Momentum built in the second half of the year especially in clinical markets, where adoption of NGS-based testing is expanding reinforces our confidence as we enter 2026."

Industry Context

StockSavvy.ai notes that Illumina's focus on expanding its multiomics portfolio through acquisitions like SomaLogic and initiatives like the Billion Cell Atlas aligns with the broader life sciences industry trend towards integrated 'omics' data for drug discovery and precision medicine. The increasing adoption of Next-Generation Sequencing (NGS)-based testing in clinical markets indicates a maturing market for genomic technologies beyond pure research.

Management Changes

Legal Proceedings

• Risk of additional litigation arising in connection with the GRAIL acquisition.
• Legal contingency and settlement expenses were $8 million in Q4 2025 and $10 million in FY 2025.

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth, strategic acquisitions, and positive future guidance, but diluted EPS from SomaLogic could be a short-term concern.
• Customers: Benefit from expanded multiomics portfolio and new data products like Billion Cell Atlas for drug discovery.
• Employees: Integration of SomaLogic employees, potential for restructuring activities (employee severance costs mentioned in non-GAAP adjustments).
• Regulatory Authorities: Continued engagement regarding China's Unreliable Entities List and regulatory clearances for products.

Next Steps

• Integration of SomaLogic, Inc. into existing operations and technology portfolio.
• Further development and commercialization of instruments, consumables, and products.
• Deployment of new products, services, and applications.
• Expansion of markets for technology platforms.
• Continued efforts to mitigate the impact of tariffs and manage China market uncertainty.

Key Dates

Recommendation

The filing indicates a clear return to growth for Illumina, with strong Q4 2025 results and optimistic revenue and EPS guidance for FY 2026. Strategic acquisitions like SomaLogic and new product launches like the Billion Cell Atlas position the company well in expanding clinical and multiomics markets. While there are integration costs and ongoing China market uncertainties, the overall trajectory and management's confidence suggest a positive outlook for long-term investors.

Keywords

Genomics, DNA sequencing, Multiomics, Proteomics, SomaLogic, NGS, Clinical genomics, Precision medicine, Biotechnology, Life sciences, Financial results, Earnings, SEC filing, ILMN, China, MOFCOM, BioInsight, Drug discovery